Switching from Beraprost to Selexipag in the Treatment of Pulmonary Arterial Hypertension: Insights from a Phase IV Study of the Japanese Registry (The EXCEL Study: EXChange from bEraprost to seLexipag Study)
Pulmonary arterial hypertension (PAH) remains a significant challenge in cardiology, necessitating advancements in treatment strategies. This study explores the safety and efficacy of transitioning patients from beraprost to selexipag, a novel selective prostacyclin receptor agonist, within a Japane...
Saved in:
Main Authors: | Yuichi Tamura (Author), Hiraku Kumamaru (Author), Ichizo Tsujino (Author), Rika Suda (Author), Kohtaro Abe (Author), Takumi Inami (Author), Koshin Horimoto (Author), Shiro Adachi (Author), Satoshi Yasuda (Author), Fusako Sera (Author), Yu Taniguchi (Author), Masataka Kuwana (Author), Koichiro Tatsumi (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2024-04-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Nanosuspensions of Selexipag: Formulation, Characterization, and in vitro Evaluation
by: Rusul M. Alwan, et al.
Published: (2021) -
Selexipag in the treatment of pulmonary arterial hypertension: design, development, and therapy
by: Hardin EA, et al.
Published: (2016) -
Effect of quercetin on the pharmacokinetics of selexipag and its active metabolite in beagles
by: Shun-bin Luo, et al.
Published: (2022) -
Cost-effectiveness analysis of selexipag for the combined treatment of pulmonary arterial hypertension
by: Wenxing Dong, et al.
Published: (2023) -
Case Report: Selexipag in pediatric pulmonary hypertension: Initiation, transition, and titration
by: Jenna M. Faircloth, et al.
Published: (2023)